Analysis of interactions between sparsentan and other drugs

Sparsentan (Sparsentan) is a targeted therapy drug mainly used to treat primary glomerular diseases, such as focal segmental glomerulosclerosis (FSGS). It has the dual mechanisms of endothelin receptor antagonist (ERA) and angiotensinII receptor blocker (ARB), playing a unique role in reducing proteinuria and delaying the deterioration of renal function. However, during clinical use, the interaction between sparsentane and other drugs cannot be ignored, and reasonable evaluation and monitoring are crucial.

Sparsentan is primarily metabolized by the CYP3A enzyme in the liver and therefore has potential interactions with drugs that affect CYP3A enzyme activity. For example, strong CYP3A inhibitors such as ketoconazole and erythromycin may increase the plasma concentration of sparsentane and increase the risk of side effects; while rifampicin and other CYP3A inducers may reduce its efficacy. Therefore, caution should be exercised when using these drugs simultaneously, and the sparsentan dose should be adjusted or replaced with an appropriate concomitant medication regimen if necessary.

Special caution is required when combined with antihypertensive drugs. Since sparsentan has antihypertensive effects, if used in combination with other vasodilators or diuretics (such as amlodipine, furosemide, etc.), the risk of hypotension may increase. Especially during the initial treatment phase or dose adjustment period, blood pressure changes need to be closely monitored to avoid the occurrence of symptomatic hypotension.

The effects of spaxantane should also be of concern in patients taking immunosuppressants (eg, cyclosporine, tacrolimus) or anticoagulants (eg, warfarin). Although clinical data are currently limited, it may alter the expression of liver enzymes and may indirectly affect the metabolism or clearance of these drugs. Therefore, it is recommended to regularly monitor blood drug concentration and coagulation function during combined use to ensure efficacy and safety. Generally speaking, individualized management should be adhered to when using sparsentane in combination, and advice from clinical pharmacists or professional physicians should be sought when necessary to ensure the rationality and safety of the treatment plan.

Reference materials:https://www.sparsentan.com/